Adma Biologics (ADMA) Share-based Compensation (2011 - 2025)

Adma Biologics has reported Share-based Compensation for 13 years, with the latest figure at $5.4 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 0.75% year-over-year to $5.4 million; the trailing twelve-month figure through Dec 2025 stood at $20.0 million (up 47.08% YoY), and the FY2025 full-year result was $20.0 million, up 47.08% from the prior year.
• Share-based Compensation for Q4 2025 stood at $5.4 million, up from $5.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.4 million in Q4 2024, with the low at $688274.0 in Q3 2021.
• Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $1.7 million in 2022.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 32.37% — and 2024, when it jumped 211.35%.
• Adma Biologics' Share-based Compensation stood at $1.2 million in 2021, then fell by 11.88% to $1.1 million in 2022, then jumped by 63.23% to $1.7 million in 2023, then jumped by 211.35% to $5.4 million in 2024, then decreased by 0.75% to $5.4 million in 2025.
• The last three Share-based Compensation figures came in at $5.4 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.